

ASSESSING THE SAFETY OF FECAL MICROBIOTA TRANSPLANTATION IN PEDIATRIC PATIENTS: A SINGLE-CENTER EXPERIENCE

Vaidotas Urbonas

UEG Week Berlin 2025

Poster

Colorectal

October 7, 2025

A retrospective single-center study of 108 fecal microbiota transplantation procedures via colonoscopy in 73 pediatric patients found no serious adverse events and only mild, self-limiting symptoms in 9.3% of cases.

KEY POINTS

- The study reviewed all pediatric FMT procedures performed between 2017 and 2024 at Vilnius University Hospital Santaros Klinikos, with patients ranging from 2.7 to 17.8 years of age (median 8.8 years).
- Primary indications were autism spectrum disorder as part of ongoing research (77.8%), Clostridium difficile infection (10.2%), inflammatory bowel disease (6.5%), and other conditions (5.6%).
- No anesthesia-related or colonoscopy-related complications occurred, and no serious adverse events were recorded across all 108 procedures.
- Mild, self-limiting adverse events such as transient diarrhea and abdominal discomfort were reported in 10 cases (9.3%); one patient developed fever and pharyngitis three days post-procedure, deemed likely unrelated to FMT.
- The authors conclude that their data support FMT via colonoscopy as a well-tolerated and safe therapeutic option in pediatric patients.

VIEW THIS CONTENT ON GUTFLIX

<https://gutflix.eu/search/d/1cb08820-a813-11f0-b72f-0242ac140006>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.